ZelleRx Corp.
This article was originally published in Start Up
Executive Summary
Imagine a type of cell that combines the advantages of a natural defense mechanism with the desirable attributes of a biopharmaceutical. The founders of ZelleRx Corp. believe they've found the best of both worlds in a particular type of natural killer cell, known as NK-92. Using the cell line, ZelleRx intends to develop cell therapies for cancer, initially renal cell carcinoma and melanoma.